We are the first company to establish a quantitative biochemistry platform for the analysis of genes interaction.
Our self-developed deep learning service model provides a comprehensive and structural strategy to determine the gene co-expression network of cancers and other diseases related to Nucleophosmin (NPM1/B23). This model provides important data for health assessment, disease diagnosis, prognosis, and treatment, and for related drug development.
Our focus has been on cancer-related research and we have successfully obtained important quantitative medical data such as ovarian cancer, breast cancer, pancreatic cancer, liver cancer (viral infection), colorectal cancer, lung cancer and other related cancer recurrence prediction, cancer stage assessment, chemoresistance, metastasis, and distinguishing low-risk and high-risk patients etc. (Specificity and Prediction Accuracy up to 100%)
Our artificial intelligence deep learning service model has sufficient scalability and can be extended to other diseases, such as viral infectious diseases (such as SARS-related coronavirus and HIV), and degenerative diseases (such as cardiovascular disease), Osteoarthritis, Alzheimer, etc.), and metabolic diseases (such as diabetes, etc.). This model quantifies the interaction between genotypes and phenotypes so that the interaction between genes can be seen, diseases’ pathogenesis and causes can be known, risks assessment can be made, drug responses and resistance can be known for treatment strategy and recommendations (both Chinese and Western medicine).
Company Details
- Employees
- 6
- Founded
- -
- Address
- 319-317 Des Voeux Rd Central, 2002,hong Kong
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://byqmed.com
- HQ
- Central & Western District
B.y. Quantitative Medicine Limited Questions
B.Y. Quantitative Medicine Limited's website is http://byqmed.com
B.Y. Quantitative Medicine Limited's LinkedIn profile is https://hk.linkedin.com/company/b-y-quantitative-medicine-limited
B.Y. Quantitative Medicine Limited has
6 employees.
View email and phone details for 6
employees at B.Y. Quantitative Medicine Limited.
B.Y. Quantitative Medicine Limited's industry is
Biotechnology Research
B.Y. Quantitative Medicine Limited's top competitors are
Rojobio,
Seva Therapeutics Inc.,
Whatflow-Whatsapp Automation,
Provectus Therapeutics,
Scrptble,
Bio-Gene Technology,
Hkcend - Hong Kong Center For Neurodegenerative Diseases (香港神經退行性疾病中心),
Aavective, Inc.,
Bio.ai Thinktank,
Hong Kong Nova Limited.
B.Y. Quantitative Medicine Limited's categories are Biotechnology Research
B.Y. Quantitative Medicine Limited's founding year is 2018
